Hannah Davidson, NP
Adult Health · Denver, CONPI 1467005199
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $728, more than ten times the $67 reported in 2021.
Across 101 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$319
- Bristol Myers Squibb$213
- Johnson & Johnson$196
- Incyte Corporation$159
- Astellas Pharma US Inc$142
- Pharmacyclics LLC, An Abbvie Company$109
- plus $934 from 27 others
What the payments were for
- Food & beverage$2,071100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $319 |
| Bristol Myers Squibb | 9 | $213 |
| Johnson & Johnson | 10 | $196 |
| Incyte Corporation | 7 | $159 |
| Astellas Pharma US Inc | 7 | $142 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $109 |
| Novartis | 3 | $80 |
| Legend Biotech USA Inc. | 4 | $77 |
| Pfizer | 4 | $76 |
| Geron Corporation | 2 | $66 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Merck | 4 | $58 |
| Sobi, Inc | 2 | $54 |
| Ipsen Biopharmaceuticals, Inc | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Genmab U.S., Inc. | 2 | $42 |
| Sanofi | 2 | $35 |
| Taiho Oncology, Inc. | 2 | $27 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Gilead | 1 | $25 |
| Beigene USA, Inc. | 1 | $23 |
| Syndax Pharmaceuticals, Inc. | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Adaptive Biotechnologies Corporation | 1 | $14 |
| ADC Therapeutics America, Inc. | 1 | $14 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
| Amgen | 1 | $14 |
How this compares
$2,071 in reported general payments places this provider in the 80th percentile of 430 adult health providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 33 | $575 |
Paid to pharmacies, not to this prescriber.
Other adult health in Denver
- Toni StandleyDenver$23K
- Sarah MetzDenver$7K
- Caroline VickersDenver$6K
- Rebecca RwubusisiDenver$5K
- Megan HillDenver$4K
- Peter PrutchDenver$3K
- Stefanie EymarAurora$36K
- Jamie ThompsonColorado Springs$31K
- Alexandra GravesAurora$18K
- Keri HalsemaAurora$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.